Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy G1 Therapeutics stock | 13.19

Own G1 Therapeutics stock in just a few minutes.

Posted

Fact checked

G1 Therapeutics, Inc is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 104 staff and has a trailing 12-month revenue of around USD$2.1 million.

How to buy shares in G1 Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for G1 Therapeutics. Find the stock by name or ticker symbol: GTHX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until G1 Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$13.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of G1 Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of G1 Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted G1 Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, G1 Therapeutics's share price has had significant negative movement.

Its last market close was USD$13.19, which is 26.56% down on its pre-crash value of USD$17.96 and 49.89% up on the lowest point reached during the March crash when the shares fell as low as USD$8.8.

If you had bought USD$1,000 worth of G1 Therapeutics shares at the start of February 2020, those shares would have been worth USD$527.95 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$652.64.

G1 Therapeutics share price

Use our graph to track the performance of GTHX stocks over time.

G1 Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$13.19
52-week range USD$8.8 - USD$31.38
50-day moving average USD$13.8937
200-day moving average USD$16.2641
Wall St. target price USD$56.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.703

Buy G1 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy G1 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

G1 Therapeutics price performance over time

Historical closes compared with the close of $13.19 from 2020-11-16

1 week (2020-11-20) 4.60%
1 month (2020-10-30) 20.02%
3 months (2020-08-28) -13.51%
6 months (2020-05-29) -22.27%
1 year (2019-11-29) -38.94%
2 years (2018-11-29) -66.54%
3 years (2017-11-29) -37.49%
5 years (2015-11-26) N/A

G1 Therapeutics financials

Revenue TTM USD$2.1 million
Gross profit TTM USD$0
Return on assets TTM -28.45%
Return on equity TTM -50.35%
Profit margin 0%
Book value $5.377
Market capitalisation USD$499.1 million

TTM: trailing 12 months

Shorting G1 Therapeutics shares

There are currently 6.9 million G1 Therapeutics shares held short by investors – that's known as G1 Therapeutics's "short interest". This figure is 39.6% up from 4.9 million last month.

There are a few different ways that this level of interest in shorting G1 Therapeutics shares can be evaluated.

G1 Therapeutics's "short interest ratio" (SIR)

G1 Therapeutics's "short interest ratio" (SIR) is the quantity of G1 Therapeutics shares currently shorted divided by the average quantity of G1 Therapeutics shares traded daily (recently around 810080.61465721). G1 Therapeutics's SIR currently stands at 8.46. In other words for every 100,000 G1 Therapeutics shares traded daily on the market, roughly 8460 shares are currently held short.

However G1 Therapeutics's short interest can also be evaluated against the total number of G1 Therapeutics shares, or, against the total number of tradable G1 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case G1 Therapeutics's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 G1 Therapeutics shares in existence, roughly 180 shares are currently held short) or 0.2946% of the tradable shares (for every 100,000 tradable G1 Therapeutics shares, roughly 295 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against G1 Therapeutics.

Find out more about how you can short G1 Therapeutics stock.

G1 Therapeutics share dividends

We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.

G1 Therapeutics share price volatility

Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $8.8 up to $31.38. A popular way to gauge a stock's volatility is its "beta".

GTHX.US volatility(beta: 2.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.0521. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

G1 Therapeutics overview

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site